Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jonathan Baden"'
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Autor:
Jie He, David Fabrizio, Jonathan Baden, Parul Doshi, James Pratt, Lee A Albacker, Geoffrey R Oxnard, Gina Fusaro, Natallia Kalinava, Dean C Pavlick, Ericka M Ebot, Hanna Tukachinsky, George Green
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor genome, as determined from tumor tissue (t
Externí odkaz:
https://doaj.org/article/67f683c42d324745bba4fb1c1790f1d3
Autor:
Jeff Allen, Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary, Wangjuh (Sting) Chen, Jen-Hao Cheng, Dinesh Cyanam, Jennifer S Dickey, Elena Helman, Joerg Maas, Arnaud Papin, Rajesh Patidar, Katie J Quinn, Hongseok Tae, Christine Ward, Mingchao Xie, Ahmet Zehir, Manfred Dietel, Mark Stewart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundTumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to im
Externí odkaz:
https://doaj.org/article/e8663839837544db9634250292b948f0
Autor:
Kyle M. Hernandez, Kelli S. Bramlett, Phaedra Agius, Jonathan Baden, Ru Cao, Omoshile Clement, Adam S. Corner, Jonathan Craft, Dennis A. Dean, Jonathan R. Dry, Kristina Grigaityte, Robert L. Grossman, James Hicks, Nikki Higa, Timothy R. Holzer, Jeffrey Jensen, Donald J. Johann, Sigrid Katz, Anand Kolatkar, Jennifer L. Keynton, Jerry S.H. Lee, Dianna Maar, Jean-Francois Martini, Christopher G. Meyer, Peter C. Roberts, Matt Ryder, Lea Salvatore, Jeoffrey J. Schageman, Stella Somiari, Daniel Stetson, Mark Stern, Liya Xu, Lauren C. Leiman
Publikováno v:
The Journal of Molecular Diagnostics. 25:143-155
Publikováno v:
Expert review of molecular diagnostics. 22(7)
Autor:
Diana Merino Vega, Katherine K. Nishimura, Névine Zariffa, Jeffrey C. Thompson, Antje Hoering, Vanessa Cilento, Adam Rosenthal, Valsamo Anagnostou, Jonathan Baden, Julia A. Beaver, Aadel A. Chaudhuri, Darya Chudova, Alexander D. Fine, Joseph Fiore, Rachel Hodge, Darren Hodgson, Nathan Hunkapiller, Daniel M. Klass, Julie Kobie, Carol Peña, Gene Pennello, Neil Peterman, Reena Philip, Katie J. Quinn, David Raben, Gary L. Rosner, Mark Sausen, Ayse Tezcan, Qi Xia, Jing Yi, Amanda G. Young, Mark D. Stewart, Erica L. Carpenter, Charu Aggarwal, Jeff Allen
Publikováno v:
JCO precision oncology. 6
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncer
Publikováno v:
Cancer Research. 83:5580-5580
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) is characterized by an immunosuppressive tumor microenvironment resulting in resistance to single agent immunotherapy, and several combination strategies are being clinically evalu
Autor:
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor Ciuleanu, Anthony Goncalves, Neeltje Steeghs, Patrick Schöffski, Paolo A. Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S. Tan, Jennifer E. Friedmann, Jacqueline Vuky, Marina Tschaika, Ruta Slepetis, Georgia D. Kollia, Misena Pacius, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Publikováno v:
Cancer Research. 82:CT022-CT022
High tumor mutational burden assessed in tissue biopsies (tTMB-H) or blood (bTMB-H) is associated with clinical efficacy in patients treated with immunotherapies. CheckMate 848 (NCT03668119) is a prospective phase 2 study of nivolumab (NIVO) with or
Autor:
Jie He, Natallia Kalinava, Parul Doshi, Jie Ma, Dean C. Pavlick, Lee A. Albacker, Hanna Tukachinsky, Gina Fusaro, Geoffrey R. Oxnard, George Green, David Fabrizio, Jonathan Baden
Publikováno v:
Cancer Research. 82:2139-2139
Tumor mutational burden (TMB) derived from tissue biopsies (tTMB) has been associated with clinical efficacy in patients treated with immune checkpoint inhibitors; the clinical utility of TMB derived from blood samples (bTMB) has also been demonstrat
Autor:
Tatiana Vener, Carlo Derecho, Dondapati Chowdary, Haiying Wang, Georg Schäfer, Shobha Varde, Sebastian Mannweiler, Peter Amersdorfer, Marco Auprich, Howard Robin, Alexandre E. Pelzer, Yashoda Rajpurohit, Jonathan Baden, Joanne Skelton, Bradley C. Leibovich, Abhijit Mazumder, Jyoti Mehrotra, Walt Stallings
Publikováno v:
Clinical Chemistry. 54:874-882
Background: Several studies have demonstrated the value of DNA methylation in urine-based assays for prostate cancer diagnosis. However, a multicenter validation with a clinical prototype has not been published. Methods: We developed a multiplexed, q